These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
339 related articles for article (PubMed ID: 9237325)
1. Activity of raloxifene in immature and ovariectomized rat uterotrophic assays. Ashby J; Odum J; Foster JR Regul Toxicol Pharmacol; 1997 Jun; 25(3):226-31. PubMed ID: 9237325 [TBL] [Abstract][Full Text] [Related]
2. Uterotrophic effects of tamoxifen, toremifene, and raloxifene do not predict endometrial cell proliferation in the ovariectomized CD1 mouse. Carthew P; Edwards RE; Nolan BM Toxicol Appl Pharmacol; 1999 Jul; 158(1):24-32. PubMed ID: 10387929 [TBL] [Abstract][Full Text] [Related]
3. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. Black LJ; Sato M; Rowley ER; Magee DE; Bekele A; Williams DC; Cullinan GJ; Bendele R; Kauffman RF; Bensch WR J Clin Invest; 1994 Jan; 93(1):63-9. PubMed ID: 8282823 [TBL] [Abstract][Full Text] [Related]
4. The rodent uterotrophic assay: critical protocol features, studies with nonyl phenols, and comparison with a yeast estrogenicity assay. Odum J; Lefevre PA; Tittensor S; Paton D; Routledge EJ; Beresford NA; Sumpter JP; Ashby J Regul Toxicol Pharmacol; 1997 Apr; 25(2):176-88. PubMed ID: 9185893 [TBL] [Abstract][Full Text] [Related]
5. Pharmacological actions of a novel, potent, tissue-selective benzopyran estrogen. Galbiati E; Caruso PL; Amari G; Armani E; Ghirardi S; Delcanale M; Civelli M J Pharmacol Exp Ther; 2002 Oct; 303(1):196-203. PubMed ID: 12235251 [TBL] [Abstract][Full Text] [Related]
6. Characterization of the pharmacologic profile of a standardized soy extract in the ovariectomized rat model of menopause: effects on bone, uterus, and lipid profile. Gallo D; Zannoni GF; Apollonio P; Martinelli E; Ferlini C; Passetti G; Riva A; Morazzoni P; Bombardelli E; Scambia G Menopause; 2005; 12(5):589-600. PubMed ID: 16145313 [TBL] [Abstract][Full Text] [Related]
7. Regulation of gene expression by 8-prenylnaringenin in uterus and liver of Wistar rats. Diel P; Thomae RB; Caldarelli A; Zierau O; Kolba S; Schmidt S; Schwab P; Metz P; Vollmer G Planta Med; 2004 Jan; 70(1):39-44. PubMed ID: 14765291 [TBL] [Abstract][Full Text] [Related]
8. Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor beta and androgen receptor in rats. Wang XN; Simmons HA; Salatto CT; Cosgrove PG; Thompson DD Menopause; 2006; 13(4):609-20. PubMed ID: 16837883 [TBL] [Abstract][Full Text] [Related]
9. Gene expression changes in the immature rat uterus: effects of uterotrophic and sub-uterotrophic doses of bisphenol A. Ashby J; Odum J Toxicol Sci; 2004 Dec; 82(2):458-67. PubMed ID: 15456929 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators. Grese TA; Pennington LD; Sluka JP; Adrian MD; Cole HW; Fuson TR; Magee DE; Phillips DL; Rowley ER; Shetler PK; Short LL; Venugopalan M; Yang NN; Sato M; Glasebrook AL; Bryant HU J Med Chem; 1998 Apr; 41(8):1272-83. PubMed ID: 9548817 [TBL] [Abstract][Full Text] [Related]
12. Examination of the in vitro and in vivo estrogenic activities of eight commercial phthalate esters. Zacharewski TR; Meek MD; Clemons JH; Wu ZF; Fielden MR; Matthews JB Toxicol Sci; 1998 Dec; 46(2):282-93. PubMed ID: 10048131 [TBL] [Abstract][Full Text] [Related]
13. An in vivo battery for identifying endocrine modulators that are estrogenic or dopamine regulators. O'Connor JC; Cook JC; Craven SC; Van Pelt CS; Obourn JD Fundam Appl Toxicol; 1996 Oct; 33(2):182-95. PubMed ID: 8921337 [TBL] [Abstract][Full Text] [Related]
14. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate. Frolik CA; Bryant HU; Black EC; Magee DE; Chandrasekhar S Bone; 1996 Jun; 18(6):621-7. PubMed ID: 8806005 [TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene. Grese TA; Cho S; Finley DR; Godfrey AG; Jones CD; Lugar CW; Martin MJ; Matsumoto K; Pennington LD; Winter MA; Adrian MD; Cole HW; Magee DE; Phillips DL; Rowley ER; Short LL; Glasebrook AL; Bryant HU J Med Chem; 1997 Jan; 40(2):146-67. PubMed ID: 9003514 [TBL] [Abstract][Full Text] [Related]
16. Lack of (anti-) androgenic or estrogenic effects of three pyrethroids (esfenvalerate, fenvalerate, and permethrin) in the Hershberger and uterotrophic assays. Kunimatsu T; Yamada T; Ose K; Sunami O; Kamita Y; Okuno Y; Seki T; Nakatsuka I Regul Toxicol Pharmacol; 2002 Apr; 35(2 Pt 1):227-37. PubMed ID: 12052007 [TBL] [Abstract][Full Text] [Related]
17. Diabetes modulates differentially creatine kinase-specific activity responsiveness to estradiol-17beta and to raloxifene in rat organs. Somjen D; Shen M; Stern N; Mirsky N J Cell Biochem; 2006 Sep; 99(1):133-9. PubMed ID: 16598752 [TBL] [Abstract][Full Text] [Related]
18. Comparative responses of three rat strains (DA/Han, Sprague-Dawley and Wistar) to treatment with environmental estrogens. Diel P; Schmidt S; Vollmer G; Janning P; Upmeier A; Michna H; Bolt HM; Degen GH Arch Toxicol; 2004 Apr; 78(4):183-93. PubMed ID: 14689164 [TBL] [Abstract][Full Text] [Related]
19. Validation of the intact rat weanling uterotrophic assay with notes on the formulation and analysis of the positive control chemical in vehicle. Tyl RW; Marr MC; Brown SS; Dolbow EA; Myers CB J Appl Toxicol; 2010 Oct; 30(7):694-8. PubMed ID: 20981862 [TBL] [Abstract][Full Text] [Related]
20. Contraceptive, estrogenic and anti-estrogenic potentials of methanolic root extract of Carpolobia lutea in rodents. Ettebong EO; Nwafor PA; Ekpo M; Ajibesin KK Pak J Pharm Sci; 2011 Oct; 24(4):445-9. PubMed ID: 21959803 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]